An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Study of JNJ-93841937 Participants with Advanced Non-Small Cell Lung Cancer
Sponsor: Janssen
Enrolling: Male and Female Patients
IRB Number: AAAT1655
U.S. Govt. ID: NCT04077463
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC) as well as looking at the effects that lazertinib and JNJ-61186372 have when taken together. Lazertinib is taken orally and JNJ-61186372 is an intravenous drug. Lazertinib (YH25448) belongs to a class of drugs called EGFR tyrosine kinase inhibitors, which helps slow the growth or stop the cancer cells. JNJ-61186372 is an antibody. Antibodies are proteins that bind to certain targets. In test tubes and animals, JNJ-61186372 binds to two different types of targets that can be found on cancer cells.
Investigator
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have non small cell lung cancer? Yes No
Do you have symptomatic brain metastases or brain metastases requiring treatment? Yes No
Do you have significant cardiovascular disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162